Glucose metabolism after pancreas-kidney transplantation.
Simultaneous pancreas-kidney (SPK) transplantation is a promising treatment option for patients with type 1 diabetes and end-stage renal disease. Most of these patients can achieve normalization of glucose and hemoglobin A(1c) levels. Patient and graft survival continues to improve; however, defects in beta-cell function and insulin resistance can be seen over time after transplant. Various methods can be used to assess the SPK recipient for the development of hyperglycemia and graft dysfunction, with treatment aimed at minimizing diabetogenic immunosuppression, using agents that may preserve beta-cell function, and improving insulin resistance.
Diakoff
Elizabeth
E
The Ohio State University, Division of Endocrinology, Diabetes, and Metabolism, 1581 Dodd Drive, 491C McCampbell Hall, Columbus, OH 43210, USA. Elizabeth.Diakoff@osumc.edu
D001786:Blood Glucose / Q000378:metabolism; D048909:Diabetes Complications / Q000097:blood / Q000378:metabolism / Q000517:prevention & control; D005947:Glucose / Q000378:metabolism*; D006442:Glycated Hemoglobin / Q000378:metabolism; D006085:Graft Survival / Q000502:physiology; D006801:Humans; D016030:Kidney Transplantation / Q000009:adverse effects / Q000379:methods*; D016035:Pancreas Transplantation / Q000009:adverse effects / Q000379:methods*; D011183:Postoperative Complications / Q000097:blood / Q000378:metabolism / Q000517:prevention & control
D001786:Blood Glucose; D005947:Glucose; D006442:Glycated Hemoglobin